The EPS beat is notable but the stock's primary catalyst remains the Phase 2b PLATEAU trial data. With $27.6M cash, the company has runway through the interim analysis in Q1 2027. Traders should watch for any trial updates, financing needs, or partnership announcements.
Price Chart
Executive Summary
Veru reported fiscal Q2 2026 net loss of $2.7M (-$0.12/share) vs $7.9M (-$0.54/share) a year ago, beating the $-0.37 consensus by 67.6%. The company highlighted active enrollment in the Phase 2b PLATEAU trial of enobosarm for obesity, with interim analysis on track for Q1 2027.
Key Financial Metrics
Key Facts
- Net loss per share improved to -$0.12 from -$0.54 YoY, beating consensus of -$0.37
- Cash and equivalents $27.6M as of March 31, 2026, down from $33.0M at December 31, 2025
- Phase 2b PLATEAU trial of enobosarm + semaglutide actively enrolling; interim analysis expected Q1 2027
- Operating loss narrowed to $7.2M from $8.1M YoY; R&D expenses declined to $3.1M from $3.9M
Financial Impact
Net loss beat consensus by $0.25/share ($0.12 actual vs $0.37 estimated) on a GAAP basis, representing a 67.6% positive surprise.
Risk Factors
- High cash burn rate ($15.1M used in operating activities in H1 2026) could require dilutive financing
- No revenue and single-product pipeline with binary trial risk
- Clinical trial delays or negative interim results could severely impact stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-220569 |
| Document: d114190d8k.htm | 0001193125-26-220569 |
| Document: 0001193125-26-220569-index-headers.html | 0001193125-26-220569 |
| Document: 0001193125-26-220569-index.html | 0001193125-26-220569 |
| Document: 0001193125-26-220569.txt | 0001193125-26-220569 |
| 8-K Data (Synthetic) | 0001193125-26-220569 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Aug 10, 2026 11w ago | Press Release | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Jul 2, 2026 16w ago | 8-K / 424B5 | $3.06 $2.83 | ▲ +7.52% | ▲ +8.39% | $2.28 (+25.49%) |
Jun 4, 2026 20w ago | 8-K | $4.23 $3.40 | ▼ −19.62% | ▼ −17.02% | $2.28 (−46.10%) |
May 13, 2026 23w ago | 8-K | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
May 13, 2026 23w ago | Press Release | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers